Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 177, Issue -, Pages 241-248Publisher
ELSEVIER
DOI: 10.1016/j.ejpb.2022.07.005
Keywords
MAM; native MS; Monoclonal antibody; Intact protein analysis; New peak detection; Biopharmaceutical
Categories
Ask authors/readers for more resources
This study combines intact protein mass spectrometry and the multi-attribute method to create an intact multi-attribute method (iMAM) for defining and quantifying biopharmaceutical critical quality attributes. The results show the potential of iMAM for implementation at different stages of the production pipeline.
The availability of rapid methods that can accurately define and quantify biopharmaceutical critical quality attributes has been the driving force for the implementation of mass spectrometry techniques throughout the development and production pipeline. While the multi-attribute method (MAM) has become widely adopted and developed, some critical information cannot be monitored through this workflow, such as correct chain assembly or the presence of fragments or aggregates. In this study, we combine intact protein mass spectrometry and the multi-attribute method to create an intact multi-attribute method - or iMAM. Using a CFR Part 11 compliant data system, we evaluated the proposed workflow using several intact analysis approaches under both denaturing and native conditions. As for the standard MAM approach, iMAM involves the generation of an intact protein target workbook which is created from the analysis of a reference sample, with ID confirmation obtained from deconvolution results and chromatographic retention times, while quantitation is obtained from the intensities of the m/z of most abundant charge states. The created processing method is then applied to the analysis of sub-sequent samples. New peak detection can also be performed, monitoring the number of components revealed after each analysis. The entire data process can be automated to generate a report within the chromatography data system software. Three case studies presented herein show the potential of iMAM for implementation at different stages of the production pipeline, from product development to stability testing and batch release.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available